(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Pick Your Number one breakfast food - 2The most effective method to Safeguard Your Teeth from Acidic Food varieties and Beverages
- 3German petrol stations hike prices as once-a-day rule takes effect
- 4Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)
- 5Whale stranded off Germany for days found stuck again
- Volunteers aiding humpback whale stranded in Baltic get death threats
- Which Instax Camera Would it be a good idea for you to Purchase?
- Israeli media reports Iran attacking greater Tel Aviv region
- What Middle East Conflict Could Mean For The World’s Largest Whale Shark Gathering
- Eight arrested in joint Scotland and Spain gang raids
- Where You Could Sleep With Snorlax in Japan, From MIMARU’s Pokémon Rooms to Grand Hyatt Tokyo’s Limited Pokémon Suite
- Zelensky confidant dismissed from further posts amid bribery scandal
- How Would You Like to Deal with Your Funds?
- Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
